Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD8853 |
Synonyms | |
Therapy Description |
AZD8853 is a monoclonal antibody that targets GDF15, potentially leading to enhanced T cell activation and inhibition of tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 1828). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD8853 | AZD-8853|AZD 8853 | AZD8853 is a monoclonal antibody that targets GDF15, potentially leading to enhanced T cell activation and inhibition of tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 1828). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05397171 | Phase Ib/II | AZD8853 | A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours | Terminated | USA | CAN | 0 |